Mark J. Foley
Net Worth
Last updated:
What is Mark J. Foley net worth?
The estimated net worth of Mr. Mark J. Foley is at least $17,826,571 as of 3 Aug 2023. He owns shares worth $3,067,369 as insider, has earned $6,866,482 from insider trading and has received compensation worth at least $7,892,720 in Revance Therapeutics, Inc..
What is the salary of Mark J. Foley?
Mr. Mark J. Foley salary is $986,590 per year as Chief Executive Officer & Director in Revance Therapeutics, Inc..
How old is Mark J. Foley?
Mr. Mark J. Foley is 60 years old, born in 1965.
What stocks does Mark J. Foley currently own?
As insider, Mr. Mark J. Foley owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Revance Therapeutics, Inc. (RVNC) | Chief Executive Officer & Director | 840,375 | $3.65 | $3,067,369 |
What does Revance Therapeutics, Inc. do?
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Mark J. Foley insider trading
Revance Therapeutics, Inc.
Mr. Mark J. Foley has made 5 insider trades between 2017-2023, according to the Form 4 filled with the SEC. Most recently he sold 26,279 units of RVNC stock worth $593,143 on 3 Aug 2023.
The largest trade he's ever made was exercising 70,447 units of RVNC stock on 15 May 2023. As of 3 Aug 2023 he still owns at least 840,375 units of RVNC stock.
Revance Therapeutics key executives
Revance Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Abhay Joshi (62) Chief Operating Officer, Pres of R&D and Product Operations
- Mr. Dustin S. Sjuts (46) Pres
- Mr. Dwight Moxie (48) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Mark J. Foley (60) Chief Executive Officer & Director
- Mr. Tobin C. Schilke (50) Chief Financial Officer & Principal Accounting Officer